Novo Nordisk A/S (NYSE:NVO) Shares Purchased by Institute for Wealth Management LLC.

Institute for Wealth Management LLC. raised its stake in Novo Nordisk A/S (NYSE:NVO) by 3.9% in the 4th quarter, Holdings Channel reports. The institutional investor owned 12,668 shares of the company’s stock after buying an additional 474 shares during the period. Institute for Wealth Management LLC.’s holdings in Novo Nordisk A/S were worth $1,311,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in the stock. IHT Wealth Management LLC grew its holdings in Novo Nordisk A/S by 3.5% in the 4th quarter. IHT Wealth Management LLC now owns 2,369 shares of the company’s stock valued at $321,000 after buying an additional 80 shares in the last quarter. Hancock Whitney Corp increased its position in shares of Novo Nordisk A/S by 4.1% during the 1st quarter. Hancock Whitney Corp now owns 2,342 shares of the company’s stock worth $373,000 after purchasing an additional 92 shares during the last quarter. Clarius Group LLC increased its position in shares of Novo Nordisk A/S by 0.5% during the 4th quarter. Clarius Group LLC now owns 18,505 shares of the company’s stock worth $1,914,000 after purchasing an additional 93 shares during the last quarter. SRS Capital Advisors Inc. increased its position in shares of Novo Nordisk A/S by 9.6% during the 1st quarter. SRS Capital Advisors Inc. now owns 1,060 shares of the company’s stock worth $169,000 after purchasing an additional 93 shares during the last quarter. Finally, Relyea Zuckerberg Hanson LLC increased its position in shares of Novo Nordisk A/S by 3.2% during the 4th quarter. Relyea Zuckerberg Hanson LLC now owns 3,159 shares of the company’s stock worth $327,000 after purchasing an additional 99 shares during the last quarter. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Novo Nordisk A/S Stock Performance

NYSE NVO opened at $122.70 on Friday. The company has a market cap of $550.62 billion, a P/E ratio of 45.36, a P/E/G ratio of 2.05 and a beta of 0.41. The company has a debt-to-equity ratio of 0.19, a current ratio of 0.82 and a quick ratio of 0.64. The stock has a 50-day moving average of $126.39 and a two-hundred day moving average of $110.72. Novo Nordisk A/S has a 1-year low of $75.56 and a 1-year high of $138.28.

Novo Nordisk A/S (NYSE:NVO) last released its earnings results on Wednesday, January 31st. The company reported $0.71 earnings per share for the quarter, beating the consensus estimate of $0.66 by $0.05. The company had revenue of $9.51 billion during the quarter, compared to the consensus estimate of $9.14 billion. Novo Nordisk A/S had a return on equity of 90.36% and a net margin of 36.03%. As a group, analysts anticipate that Novo Nordisk A/S will post 3.32 EPS for the current year.

Novo Nordisk A/S Increases Dividend

The business also recently disclosed a Semi-Annual dividend, which was paid on Tuesday, April 2nd. Stockholders of record on Monday, March 25th were paid a $0.664 dividend. This represents a dividend yield of 0.9%. The ex-dividend date of this dividend was Friday, March 22nd. This is a boost from Novo Nordisk A/S’s previous Semi-Annual dividend of $0.22. Novo Nordisk A/S’s dividend payout ratio (DPR) is presently 49.17%.

Analyst Ratings Changes

NVO has been the subject of a number of recent analyst reports. BMO Capital Markets initiated coverage on Novo Nordisk A/S in a research report on Friday, April 12th. They set an “outperform” rating and a $163.00 price objective for the company. UBS Group initiated coverage on Novo Nordisk A/S in a research report on Tuesday, January 16th. They set a “neutral” rating for the company. Cantor Fitzgerald reissued an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a research report on Thursday. Finally, Morgan Stanley initiated coverage on Novo Nordisk A/S in a research report on Tuesday, January 23rd. They set an “overweight” rating and a $120.00 price objective for the company. Two analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $133.60.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.